{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016635","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.851281+00:00","generated_at":"2026-06-24T00:57:10.331401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Finch Therapeutics Q2 2022 net loss $22.7M; revenue down $2.5M YoY","bullets":["Net loss of $22.7M vs $15.2M in Q2 2021; R&D flat at $13.9M; G&A up to $8.2M.","Revenue fell primarily due to Takeda agreement amendment; prior period had $1.8M PPP loan gain.","Cash $104.7M as of June 30, 2022 (down from $133.5M Dec 2021); funds operations into Q1 2024.","On track to start enrollment in PRISM4 Phase 3 CP101 trial in H2 2022; topline data expected H1 2024.","PRISM-EXT results accepted for ACG 2022; FIN-211 IND submission on track for Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016635","json":"https://secwatch.observer/filing/0000950170-22-016635.json","markdown":"https://secwatch.observer/filing/0000950170-22-016635.md","text":"https://secwatch.observer/filing/0000950170-22-016635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/0000950170-22-016635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/fnch-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:57:10.331401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}